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Cardiovascular disease is America’s leading health problem
and the leading cause of death. One person in three suﬀers
from some form of cardiovascular disease. There is an urgent
need to develop new therapeutic strategies to improve the
cardiovascular diseases outcome [1]. Very recent studies
have demonstrated that the heptapeptide angiotensin (Ang)-
(1-7) holds important cardiovascular beneﬁcial eﬀects [2].
These actions are generally mediated by activation of the
G protein-coupled receptor Mas [3]. As a result of these
novel ﬁndings, Ang-(1-7), in combination with Mas and
angiotensin-converting enzyme (ACE) 2 [4, 5], the main
enzyme involved in its formation, is thought to compose a
cardioprotective branch within the renin-angiotensin system
(RAS), which balances the ACE/Ang II/AT1 receptor axis
eﬀects[6].Consequently,newtherapeuticapproachestarget-
ing the ACE2/Ang-(1-7)/Mas axis have been proposed.
In view of these new and exciting ﬁndings, we proposed
a special issue in the International Journal of Hypertension.
Our main objective was to compile original research articles
as well as review articles from outstanding investigators
around the World contributing to the continued eﬀorts to
understand the role of this axis in the cardiovascular system.
Particularly, our intention was to give some insights into the
advances in therapeutic approaches based on the ACE2/Ang-
(1-7)/Mas axis to treat cardiovascular diseases.
This special issue is composed of 15 papers (original arti-
cles and reviews). Importantly, part of them was presented in
the VIII Vasoactive Peptides Symposium which was held in
Brazil in April, 2011. This meeting was a unique opportunity
for clinicians and researchers to exchange their experience
within the cardiovascular ﬁeld focusing on the RAS.
The paper provided by N. E. Clarke and J. Turner is an
overview of the biological roles of ACE2. They focused on
the entrance of recombinant human ACE2 (rhACE2) into
clinical trials discussing the potential use of this enzyme
as a therapeutic strategy. A. J. Ferreira et al. expand this
view to the whole ACE2/Ang-(1-7)/Mas axis highlighting
the initiatives to develop potential therapeutic approaches
based on this axis. Other three papers are original articles
evaluating examples of these strategies. M. Durik et al.
investigated the eﬀects of a stabilized, thioether-bridged
analogue of Ang-(1-7) called cyclic Ang-(1-7) [cAng-(1-
7)] in rat model of myocardial infarction (MI). They
found that MI increased the heart weight and myocyte
size which was restored by cAng-(1-7) to sham levels. In
addition, cAng-(1-7) lowered left ventricular end-diastolic
pressure and improved endothelial function. The second
strategy discussed in this special issue was the Ang-(1-7)
included in hydroxypropyl β-cyclodextrin (HPβCD). F. D.
Marques et al. evaluated the chronic cardiac eﬀects of this
compound in infarcted rats. Once-a-day oral HPβCD/Ang-
(1-7) administration improved the cardiac function and
reduced the deleterious eﬀects induced by MI on TGF-β
and collagen type I expression. Finally, the antiproliferative
eﬀects of the nonpeptide AVE 0991, an agonist of Mas, were
investigated by C. Sheng-Long et al. It was observed that2 International Journal of Hypertension
AVE 0991 attenuates the Ang II-induced vascular smooth
muscle cells proliferation in a dose-dependent fashion and
that this eﬀect is associated with the Mas/heme oxygenase-
1/p38 MAPK signaling pathway.
In this special issue, the role of the ACE2/Ang-(1-7)/Mas
axis in the cardiovascular function was extensively discussed
in review articles and new ﬁndings regarding this axis were
presented.E.R.M.Gomesetal.revisedtheactualknowledge
about Ang-(1-7)-mediated signaling in cardiac cells, as well
asthediscoveriesmadeincardiomyocytephysiologythrough
the use of genetic approaches. Interestingly, M. Poglitsch et
al. reported signiﬁcant diﬀerences in the conversion rates
of recombinant human and recombinant murine ACE2
(rhACE2 and rmACE2, resp.) for diverse natural peptide
substrates in plasma samples. They found species-speciﬁc
diﬀerences in substrate speciﬁcities, probably leading to
functional diﬀerences in the alternative axis of the RAS.
Specially,incontrasttorhACE2,rmACE2issubstantiallyless
potent in transforming Ang-(1-10) to Ang-(1-9). Of note,
this enzymatic pathway was reviewed by M. P. Ocaranza and
J. E. Jalil. They presented current experimental evidence sug-
gestingthatactivationoftheACE2/Ang-(1-9)pathwaymight
protect the heart and vessels from adverse cardiovascular
remodeling in hypertension and in heart failure.
In addition to the cardiovascular system, some insights
were given in the renal system in this special issue. S.
V. B. Pinheiro and A. C. Sim˜ oes e Silva highlighted the
current understanding of the ACE2/Ang-(1-7)/Mas axis
in renal physiology and in the pathogenesis of primary
hypertension and chronic kidney disease. Also, L. C. Barroso
et al. presented some data demonstrating the renal eﬀects
of acute administration of AVE 0991 in a murine model
of renal ischemia/reperfusion. Administration of AVE 0991
promoted renoprotective eﬀects evidenced by improvement
of renal function, decreased tissue injury, prevention of
local and remote leukocyte inﬁltration, and release of the
chemokine CXCL1.
In the past few years, the understanding of the RAS has
improved signiﬁcantly. This is not only a consequence of the
identiﬁcation of novel members, but also due to advances in
the knowledge concerning the role of these components in
many tissues and cells [2, 6] .H e r e ,M .A .F .G o d o ye ta l .p r o -
vided an overview of the functional role and the molecular
pathways involved in the biosynthesis and activity of Ang-(1-
7) in diverse systems, including its actions in gastrointestinal
smooth muscles. Also, S. E. Thatcher et al. evaluated the
eﬀects of ACE2 deﬁciency in bone marrow-derived stem
cells on adipose inﬂammation and glucose tolerance in mice
fed a high-fat diet. They concluded that ACE2 deﬁciency
in these cells promotes inﬂammation in adipose tissue and
augments obesity-induced glucose intolerance. Interestingly,
J. W. Prokop et al. demonstrated that many diﬀerent genes
participating in the RAScanbe aﬀectedbytestis determining
protein(SRY),apparentlyincoordinatedfashion,toproduce
more Ang II and less Ang-(1-7).
In certain circumstances and in some tissues, AT2
receptors appear to be involved in the Ang-(1-7) eﬀects [7].
Furthermore, physical interaction between Mas and AT2 in
selected tissues such as heart has been suggested as a putative
mechanism for Ang-(1-7) actions [8]. In this special issue, R.
E.Widdop’s grouppresentsanoriginalarticledemonstrating
the relationship between Ang-(1-7) and AT2 receptors. S.
Bosnyak et al. reported that the hypotensive eﬀect of Ang-
(1-7) was dependent on the background dose of candesartan
and that this eﬀect was reversed by AT2 receptor blockade.
In aged rats, the depressor eﬀect of Ang-(1-7) was evident
but was inhibited by either AT2 or Mas receptors blockade.
Furthermore, E. S. Jones et al. reported that AT2 receptor
stimulation does not signiﬁcantly inﬂuence the antihyper-
tensive eﬀect of chronic AT1 receptor blockade but plays a
role in the regulation of vascular structure, as well as in
cardiac perivascular ﬁbrosis.
Thus, we hope that this special issue is able to make
a picture of the role of the ACE2/Ang-(1-7)/Mas axis and
of the potential therapeutic of this concept for treating
cardiovascular and related diseases. Our expectation is that
this special issue might serve as an important reference to
scientists and physicians to update their knowledge about
this contemporary theme.
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